32 results
Thumbnail

D1.33 - Patient-reported outcomes following beta-lactam antibiotic allergy delabeling work-up

Thumbnail

D1.34 - Guideline adherence and safety of AI chatbots in allergology

Thumbnail

D1.37 - Which Came First? Atopic Dermatitis or occupational Allergic Contact Dermatitis in a Surgeon with Tropomyosin-Driven IgE Cross-Reactivity

Thumbnail

D1.38 - A Generalizable High-Throughput Nanobody Discovery Platform for Airborne Allergens

Thumbnail

D1.39 - Oral Lichenoid Lesions Secondary to Contact Allergy to L-Carvone from Toothpaste: A Case Report

Thumbnail

D1.40 - Independent Sensitization to poultry meat and tuna in a food allergic young girl

Thumbnail

D1.41 - B cell responses to alarmins in type 2 inflammation

Thumbnail

D1.42 - Unusual Delayed Hypersensitivity Reaction to Different Antibiotic Families

Thumbnail

D1.44 - Primary care allergy and clinical immunology fellowship: A Delphi study of core competencies

Thumbnail

D1.45 - Selective Anaphylaxis to Salmonids with Tolerance to Other Fish

Thumbnail

D2.490 - Consistent efficacy of a seasonal 300IR birch pollen sublingual immunotherapy in children and adolescents during worst pollen exposure: results of the YOBI trial

Thumbnail

D2.491 - Efficacy of a 300IR birch liquid sublingual immunotherapy during the alder and hazel pollen seasons: results of the YOBI trial

Thumbnail

D2.492 - Efficacy and safety of a 300IR daily dose of a SLIT of birch pollen allergen extract in children and adolescents with allergic rhinoconjunctivitis: results from the YOBI trial

Thumbnail

D2.494 - Tralokinumab treatment in adults with atopic dermatitis who were previously treated with dupilumab: 12-months real-world data from the TRACE study

Thumbnail

D2.495 - Treatment with Izicopan (INF904), an oral anti-C5aR inhibitor improves efficacy and safety in patients with chronic spontaneous urticaria: results from a Phase 2a study

Thumbnail

D2.496 - First-in-Human Phase I Clinical Outcomes of BxC-I17e Enriched with HSP70/miR-22-3p in Atopic Dermatitis

Thumbnail

D2.497 - Oral Deucrictibant Immediate-Release Capsule for On-Demand Treatment of Hereditary Angioedema Attacks: Results of the Phase 3 RAPIDe-3 Trial

Thumbnail

D2.498 - Berotralstat Decreased HAE Attacks Treated with On-Demand Therapy or Utilizing Professional Care in Pediatric Patients Aged 2 to

Thumbnail

D2.499 - Immunoregulatory Effects of Dupilumab Added to Omalizumab-Facilitated Multi-Allergen Oral Immunotherapy in the COMBINE clinical trial

Thumbnail

D2.503 - LP-003 Injection for the treatment of H1 Antihistamine-Inadequately Controlled Chronic Spontaneous Urticaria (CSU): A Multicenter, Randomized, Double-Blind, Controlled Phase Ⅱ Study